Facebook
Twitter
RSSGastrointestinal cancer drug shows promise
4th April 2012Bayer has said that its cancer drug has improved chances of survival in patients suffering from a type of gastrointestinal tumour and kept the condition from worsening, following a 199-patient late-stage trial.
Findings showed that a combination of Bayer’s tumour-fighting drug regorafenib and best supportive care prolonged survival in patients with metastatic gastrointestinal stromal tumours or GIST, when compared with a dummy drug and best supportive care. Bayer now plans to file for US approval for regorafenib to treat metastatic GIST.
Share this page
Comments
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Article Information
Title: Gastrointestinal cancer drug shows promise
Author:
Mark Nicholls
Article Id: 21585
Date Added: 4th Apr 2012
Sources
Recent Related Articles
Cancer rates rising in men in the UK
Largest cancer database launched
Half of people in UK will get cancer in lifetime
75% increase in drugs to treat alcoholism
Early lung cancer spotted with low-dose CT scan
Pioneering cancer gene testing announced
Radiation-based prostate cancer drug approved
Creative arts may help cancer patients with anxiety
Breast cancer screening recall
Under-50s breast cancer tops 10,000 a year
